Eli Lilly blows past quarterly estimates, hikes outlook as Zepbound and Mounjaro sales skyrocket
B2BApril 30, 2026via CNBC Tech

Eli Lilly blows past quarterly estimates, hikes outlook as Zepbound and Mounjaro sales skyrocket

Lilly hiked its full-year sales outlook by $2 billion, and also raised its adjusted profit guidance.

Enterprise buyers and decision-makers should pay attention — this could impact AI procurement and implementation strategies across industries.

Why it matters for your wallet: Every major AI industry move creates earning opportunities — from new tools to invest in, skills to learn, or markets to enter. Tracking these developments is how you stay ahead.

Read the full story on CNBC Tech →

Share:𝕏